Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

NZ sharemarket dips as big stocks weigh despite KMD gains
Markets

NZ sharemarket dips as big stocks weigh despite KMD gains

The NZ sharemarket closed down, although KMD Brands lifted on a positive result.

Tom Raynel 19 Nov 2025
Investor days to test gentailer plans for new build and firming
Markets

Investor days to test gentailer plans for new build and firming

Investors want answers on build delays, capital plans and Huntly’s future.

Ian Llewellyn 19 Nov 2025
Argosy delivers strong first-half results
Economy

Argosy delivers strong first-half results

Earnings and net tangible asset value per share up. 

Andy Macdonald 19 Nov 2025
Asset Plus' first-half profit lower as Munroe Lane in focus
Economy

Asset Plus' first-half profit lower as Munroe Lane in focus

First-half net tangible assets per share down on the year. 

Andy Macdonald 19 Nov 2025